The Avon Longitudinal Study of Parents and Children (ALSPAC) has collected detailed phenotypic and environmental information from pregnancy onwards on , 14 000 babies born in 1991-1992. A DNA bank on over 10 000 mothers and children has been established with generic consent for (undisclosed) genetic analysis, and cell lines on both children and parents are planned. As a multigenerational population cohort unselected by disease, trait or exposure, ALSPAC is uniquely placed to explore the genetic and environmental determinants of adverse developmental responses and common disease. Added value for genetic epidemiology generally is the ability to detect distortion of the expected Mendelian 50:50 transmission of alleles to study subjects (e.g. due to differential loss of embryos of one genotype) or to test for heterosis, i.e. whether heterozygotes have a greater or lesser effect than either homozygote. Finally, phenome scans (a fixed format analysis of the associations between a genotype of interest and thousands of outcome variables from the cohort database) could be used as a screening tool to test whether certain classes of genetic variation have more impact than others on human health and development.
The Avon Longitudinal Study of Parents and Children (ALSPAC) (formerly the Avon Longitudinal Study of Pregnancy and Childhood) is a population-based, prebirth cohort recruited from all pregnant women resident in three former (Avon) Health Districts with an expected date of delivery between 1 April 1991 and 31 December 1992 (1) (www.alspac,bris.ac.uk). Over 14 000 pregnant women, representing , 85% of the eligible population, enrolled in the study, and over 70% remain involved in the study to date. A 10% subsample, 'Children in Focus', was randomly selected from the last 6 months of births in the cohort. They were examined at 4, 8 and 12 months and thereafter at 6-monthly intervals until 5 years, and this allowed some initial genotyping studies focused on early growth (2, 3) . The general details of the cohort are described by Golding et al. (4) .
The 'genetic' aim cannot be separated from the overall aim of ALSPAC, namely, 'identification of the ways in which the physical and social environment interact, over time, with the genetic inheritance to affect the individual's health, behaviour and development'. In other words, the aim is to understand variation in the developmental responses to environmental stresses and trends with respect to the impact on common disease risk. A primary source of the variation in developmental response is the evolved functional diversity of gene and other DNA sequences and the combination of these transmitted to the ALSPAC study children. Additional variation comes from the epigenetic modification of gene expression as a consequence of stochastic events or in response to the environment at different stages of development. 'Environment' in this context includes maternal/intrauterine, physical, nutritional and psychosocial influences and exposure to infections, drugs and xenobiotic agents. The 'developmental' period is from conception to completion of adolescence. Thus, the long-term 'genetic' aim of ALSPAC is to understand the important genetic and epigenetic influences during development with respect to the health of children and the adults they become.
There has been a rather poor return on genetic association studies in complex, common diseases (5, 6) , and there is a tendency to interpret the poor yield from studies so far as evidence that the genetic influences on common disease are due to 'loci of small effect'. This interpretation leads to calls for larger and larger studies and better-matched controls, and to great concern over the sources of error and bias, such as systematic genotyping errors or population stratification (7, 8) . Clearly, it is important to address sources of error and bias, and use adequately powered samples for replication studies, but it is foolish to imagine that these factors and the size of studies per se are the main reasons for the lack of progress. Quite simply, the proper study of multifactorial traits or disorders demands the analysis of all the likely multiple factors in the same subjects over time. It is a question not so much of gene loci of small effect, but more of loci of contingent effect. Studies need to take account of environmental influences in the widest sense (nutrition, physical and noxious exposures, infections and psychosocial challenges), gene-gene interactions and probably transgenerational effects as well. This is easier said than done, and only makes economic and scientific sense as part of a comprehensive general population (pre-) birth cohort with high-quality measurements. Not only are birth cohorts, such as ALSPAC, a powerful design for the study of common disease, but they also provide information that can enhance the return from many costly case-control studies. This is particularly so, if the birth cohort design is multigenerational.
The broad ALSPAC 'evolved response' model
Just stating the truism that common disease and complex traits result from a combination of genetic and environmental influences does not get us very far. But a relatively simple development of this theme can be helpful in defining those aspects that have to be borne in mind in study design. Take, for example, common disorders that can increase rapidly in population prevalence, such as obesity, type 2 diabetes or asthma, where the rate of change makes people comment, 'it can't be genetic', or causes the more openminded to say, 'it can't be genetic in the usual sense of the word'. What could be the nature of such sudden changes and what are the time relationships between the determinants and the observed rise? One plausible model is that an 'evolved homeostatic (or rather homeodynamic) response mechanism' has been operating close to the limit of its 'buffering' capacity, and a small extra-environmental stress tips a significant number into decompensation, that is, the downward spiral of pathology. However, the outcomes of medical interest are not likely to be the prime targets for the evolved regulatory response; for example, obesity or cancer risk might be linked to responses evolved to optimize growth, development and reproduction, so these latter outcomes need to be included in the study. With this model, the ultimate aim must be to understand the underlying evolved regulatory response. By evolutionary necessity, this will be a coherent, if complex, set of gene-gene and gene-environment interactions, and therefore its discovery is a tractable task. This basic understanding is particularly important in the study of the early origins of adult-onset disease. Some people are concerned about the huge investment in longitudinal studies that include environmental information because of the apparent catch-22 that by the time one ascertains the disease outcomes and can establish the association for certain, the environment has 'moved on'. Thus, there is a risk that one would try to intervene on the basis of old data no longer applicable to the new situation, and the outcome could be different from what is predicted. The answer is to understand the basic evolved response, of which these life-span associations are an expression. Clearly, there have to be somewhat different scenarios for thinking about, for example, genetic variation in responses to infections, drugs and some pollutants that often involve novel exposures.
The medical genetic focus
It is worth remembering that population and evolutionary geneticists are interested in the 'works', while medical geneticists and epidemiologists are interested in 'the spanner in the works'. The two interests need different, but complementary approaches to reveal the role of genetic variation in determining the differences between people. We are largely ignorant of what class or classes of genetic variant are most influential in terms of health and disease. Stable single nucleotide polymorphisms (SNPs) that can be easily genotyped may turn out to be more useful in defining blocks of linkage disequilibrium (LD) and the genetic architecture of different populations than in revealing diseaserisk alleles, especially by using indirect haplotype approaches on which HapMap, the international project to describe genome-wide LD patterns in the main human populations, is predicated (9) . Not only does the predictive accuracy of haplotype 'tags' drop rapidly when LD is low, but these low-LD regions may harbour aetiological variants that are not in sufficient LD to be detected by the massive marker sets being planned. Indeed, these low-LD regions could be enriched for disease-risk variants, if what is breaking up the LD is also generating the aetiological variants, such as gene conversion at recombination 'hot spots' (10) .
It is also worth noting that there is no reason to assume that the outcome of medical interest will follow immediately after whatever triggers the 'incompetent' response (or rather 'incompetent response' from a medical perspective). The gap between trigger and (some) outcomes may be decades, even across generations (11 -13).
The ALSPAC genetic resource ALSPAC was designed from the start to include genetic influences among the factors to be studied for their effect on health and development. It is quite possible that putting genetic variation in context, alongside dietary, infectious, psychosocial and other environmental factors, contributed to the high proportion of study mothers giving their consent to 'generic' (undisclosed) DNA analysis. There is reconsent every time further www.eje.org blood is taken. Maternal blood for DNA extraction was collected during pregnancy, and although umbilical cord blood was collected, the primary sample from the study child was taken at the 7-year research clinic. The challenges involved in establishing the ALSPAC DNA bank have been discussed elsewhere (14) .
The ALSPAC DNA bank currently (summer 2004) comprises the following:
. children (cases, not samples) (10 232) . mothers (10 364) . partners (886) . mother/singleton 'duos' (6669) . mother/twin 'duos' (99) . validated 'trios' (700).
Collection of further parental blood samples is planned in conjunction with the generation of Epstein -Barr virus (EBV)-transformed cell lines, which has been funded by the Wellcome Trust for all possible children and parents. The peripheral blood lymphocytes for cell-line generation on the children were collected at the 9-and 11-year clinics; 6311 samples so far. A purpose-built ALSPAC population genetics laboratory that houses a robot-assisted cell-line facility was opened in November 2003. The current transformation success rate is greater than 99%.
The reasons for planning a cell-line backed genetic resource are as follows: (i) to provide a renewable source of high-quality DNA; (ii) to release 'native' genomic DNA for methylation profile analysis (for epigenetic studies), comparative genomic hybridization (for gene copy number polymorphisms) and telomere length studies; (iii) to have living cells for future 'wholegenome' interrogation.
Needless to say, the value of DNA samples is dependent on the information attached to them, and the aims of ALSPAC will be achieved only if the collection of phenotypic measures and environmental data in sufficient breadth and detail is maintained throughout development.
ALSPAC's potential to contribute to 'generic' issues in genetic epidemiology
The ALSPAC design complements case-control designs in many ways. For example, unlike case-control studies, ALSPAC is well suited to study protective genetic factors, of which perhaps the best known is the phenomenon of 'heterozygous advantage'. This is one of the more robust ways in which genetic variation can be maintained in populations, because heterozygous £ heterozygous matings also produce both types of homozygotes (see 'heterosis' below). A multigenerational population (pre-) birth cohort that is unselected by disease, trait or exposure can also contribute important information that is needed for optimal statistical analysis in genetic epidemiology generally. Two rather neglected but important areas that can be addressed are segregation (transmission) ratio distortion and heterosis.
Segregation ratio distortion
When a heterozygote forms gametes, there is an expectation that there will be an equal number carrying one allele as carries the other. This is the basis of the segregation ratios observed by Mendel. There are, however, known examples where this is not the case, right from the process of gamete formation itself through to differential loss of embryos of a particular genotype. At the population level, the regular 50:50 transmission of alleles is one of the elements reflected in the HardyWeinberg distribution of human genotypes. For given stable allele frequencies, and without assortative mating as in inbreeding, the distribution of heterozygotes to the two homozygotes remains the same over the generations; there is Hardy -Weinberg equilibrium.
Transmission tests and sib-pair analysis assume that the regular Mendelian segregation ratios hold true at the time of ascertaining the outcome of interest (15). This is not easy to study properly because it needs parent -child samples unselected by disease or exposure; therefore, it tends to be a topic that is overlooked for want of data. However, there are suggestive examples (16, 17) . The most intriguing is the genderspecific distortion at birth of the Hardy -Weinberg distribution (opposite direction in male and females) of BRCA2 (18) . Segregation ratio distortion is not only important for people analysing family data, but is also of biomedical interest in its own right. The journey from gamete formation to birth is the most hazardous of all, and selection against or for particular genotypes is likely to be common. Indeed, with recognition of the likely fetal origins of common adult disease (13) and the possible role of transgenerational responses (11, 12) , understanding this selection is of great biomedical importance.
The challenge is that segregation ratio distortion has to be studied gene by gene! While a start can be made by checking selected genes of interest, a comprehensive analysis will need to be tied in with 'whole-genome' resequencing of a suitable 'unselected' general population. Of course, thousands of trios could be recruited anew from the general population, but why fund resequencing on a sample with no other information? Clearly, better value for money from 'whole-genome' resequencing will come from using cohorts that already have detailed information on the study subjects, and the best value will come from the most suitable cohorts, namely, large population studies (unselected by phenotype or exposure) in which there is detailed, longitudinal, comprehensive information on phenotype and environment (diet, infections, noxious exposures and psychosocial circumstances). After all, the extent of segregation ratio distortion itself may depend on prevailing environmental pressures. Understanding current selection for and against human genotypes in defined environments is not the prime reason for funding expensive cohorts and their DNA sequencing, but it does represent wonderful added value by generating results that will inform the analysis of data generated at great expense from many other disease-specific studies.
Heterosis
Heterosis (which can be gender specific) is the phenomenon in which the heterozygote has a greater or lesser effect than either homozygote (19) . The potential importance of heterosis in what Haldane called 'the statics of evolution' (20) and the associated phenomenon of balancing selection was dismissed for many decades, but it has had a resurgence of late (19, 21) . The 'bad press' was initially based on evolutionary genetic grounds (22) now refuted (23) . It is clearly wise to be wary of overenthusiastic post hoc subgroup analysis by those on a mission, but a dismissive attitude runs a serious risk of throwing some important babies out with the bathwater! Heterosis has been observed in a meta-analysis of the association between the 5HTT gene and neuroticism (24), and we have some preliminary, unpublished ALSPAC evidence that it occurs in males in relation to the association of birth weight with the angiotensin-converting enzyme (ACE), insertion-deletion polymorphism (Humphries et al. personal communication). Reliable exclusion or demonstration of heterosis is not only important in its own right, but is also relevant to the genetic models used in association analysis, many of which assume that if one is not dealing with an autosomal dominant/recessive situation, the heterozygous effect will be intermediate between each homozygote.
The use of ALSPAC as a systematic screen for genetic effects on human phenotypes
The arguments for (pre-) birth cohorts, particularly if prospective information has been collected from the parents during pregnancy, and then followed up to obtain detailed phenotypic and environmental exposure information over time, have been well rehearsed. In their commentary (25) In ALSPAC, we have called this approach to seeking novel genotype -phenotype associations, the 'phenome scan'. It is essentially the inverse of the 'genome scan' in that the total population is genotyped for a functional variant or variants at a particular locus and association is sought with each of the whole range of recorded phenotypes. Thus, the ALSPAC phenome scan is a fixed-format analysis of the associations between a variable of interest (such as a genotype) and thousands of outcome variables from the ALSPAC data resource. Currently being developed, the initial prototype was based on data from the first six childbased questionnaires and measures from the 'Children in Focus' 10% subgroup (who attended a 6-monthly research clinic during the first 5 years). This gives 1760 variables presented in , 240 topic-specific tables as a PDF document.
An initial analysis displays the number of observed associations (at specified P values) compared with the number of associations expected by chance. At this first level of analysis, the general impact of one genetic variant on health and development compared with another can be assessed, without needing to know which are the 'false' associations. One just knows that this variant has more excess 'hits' than the other. This approach essentially uses the ALSPAC cohort phenotype database as a 'whole human geneeffect screening chip' and could be usefully used to compare one class of variants with another. Herein lies a potentially useful and timely contribution to genetic epidemiology generally.
Increasingly, the question facing people planning genetic association studies is which genetic variants to use. Are there particular classes of genetic variant that are more likely to influence human health and development than others? This question has been addressed in the discussion of candidate-gene approaches (26) , but selection on general molecular genetic grounds would benefit from having an actual 'test bed' such as the ALSPAC phenome scan. Many regard non-conservative changes in coding regions of genes as prime candidates (ALSPAC is piloting large-scale non-synonymous SNP analysis with the Wellcome Trust Sanger Institue), but it may be that variation in the promotor regions or similar regulatory regions around genes (non-coding cis-regulatory DNA sequences) will prove to be more important for common disease (27) .
In conclusion, ALSPAC's genetics strategy can be summarized as follows:
. to develop a resource for genetic epidemiology that is robust in the face of new discoveries (such as developments in epigenetics) . to complement case-control studies and address some 'generic' issues in genetic epidemiology . to take a developmental and multigenerational approach . to include quantitative/'intermediate' measures, in addition to 'disease' categories . to integrate genotype, phenotype and exposure information for systematic analysis and create a phenome scan library . to maximize access by the scientific community to the ALSPAC data, while maintaining the trust and privacy of the study participants.
